神経科市場：BCCによる調査の概要

世界の神経科の市場規模は、2024年の673億米ドルから、予測期間中はCAGR 7.1%で推移し、2029年には948億米ドルに達すると予測されています。

多発性硬化症の部門は、2024年の225億米ドルから、CAGR 3.9%で推移し、2029年には272億米ドルに達すると予測されています。脳腫瘍の部門は、2024年の29億米ドルから、CAGR 12.6%で推移し、2029年には53億米ドルに達すると予測されています。

当レポートでは、世界の神経科の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、パイプラインの動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場概要

第2章 市場概要

• 概要
• ポーターのファイブフォース分析
• 神経科における医療コード化と請求の課題
• 段階的治療
• Medicare削減
• コーディングエラー
• モディファイアの使用
• 文書化
• 補償範囲と事前承認
• コンプライアンスと監査
• 償還率と拒否
• 医師の支払いの課題
• 評価と管理 (E/M) - 適切なレベルのケアを請求
• 契約交渉

第3章 市場力学

• 市場力学
• 市場促進要因
• 神経疾患を持つ高齢者人口の増加
• 神経疾患の世界の発生率の増加
• 政府とNGOによる意識啓発活動
• 神経科における調査イニシアチブ
• 市場抑制要因
• ブランド医薬品の特許切れとジェネリック医薬品の出現
• 副作用
• 医薬品開発の高コスト性

第4章 新たな動向とパイプライン分析

• 新たな動向
• 神経疾患における精密医療
• 神経疾患に対する遺伝子治療
• 神経変性と幹細胞治療
• 神経科におけるナノテクノロジー
• バーチャルリアリティとデジタル治療
• 総論
• パイプライン分析

第5章 規制状況

• 概要
• 学際的バリューストーリー
• 高品質の患者報告アウトカムデータ
• EUと米国の新法の影響
• 総論

第6章 市場セグメンテーション分析

• セグメント別内訳
• 市場分析：適応症別
• パーキンソン病
• アルツハイマー病
• 精神病性障害
• てんかん障害
• 自閉症スペクトラム障害
• 脳腫瘍
• 多発性硬化症
• その他
• 地理的内訳
• 市場分析：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 競合情報

• パーキンソン病治療薬の企業シェア分析
• アルツハイマー病治療薬の企業シェア分析
• 抗精神病薬の企業シェア分析
• 抗てんかん治療薬の企業シェア分析
• 自閉症スペクトラム障害治療薬の企業シェア分析
• 脳腫瘍治療薬の企業シェア分析
• 多発性硬化症治療薬の企業シェア分析

第8章 付録

• 調査手法
• 出典
• 略語
• 企業プロファイル
• ABBVIE INC.
• ALPHA COGNITION
• BIOGEN
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• OTSUKA HOLDINGS CO. LTD.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• UCB S.A.

List of Tables

• Summary Table : Global Neurology Market, by Disease Indication, Through 2029
• Table 1 : Navigate New Neurology-related Codes
• Table 2 : Adverse Side Effects of Some Neurological Drugs
• Table 3 : List of Some Clinical Trial Drugs for Parkinson's Disease in Phase 3 and 4
• Table 4 : List of Some Clinical Trial Drugs for Alzheimer's Disease in Phase 3 and 4
• Table 5 : List of Some Clinical Trial Drugs for Epilepsy Disorder in Phase 3 and 4
• Table 6 : List of Some Clinical Trial Drugs for Autism Spectrum Disorders in Phase 3 and 4
• Table 7 : List of Some Clinical Trial Drugs for Brain Tumors in Phase 3 and 4
• Table 8 : List of Some Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4
• Table 9 : Global Neurology Market, by Disease Indication, Through 2029
• Table 10 : Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2029
• Table 11 : Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2029
• Table 12 : Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2029
• Table 13 : Global Neurology Market for Alzheimer Drugs, by Region, Through 2029
• Table 14 : Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2029
• Table 15 : Some Novel Antipsychotic Drug Targets and Therapeutic Characteristics
• Table 16 : Global Neurology Market for Antipsychotic Drugs, by Region, Through 2029
• Table 17 : Global Neurology Market for Anti-Epileptic Drugs, by Drug Class, Through 2029
• Table 18 : Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2029
• Table 19 : Global Neurology Market for ASD Therapeutics, by Label Information, Through 2029
• Table 20 : Global Neurology Market for ASD Therapeutics, by Region, Through 2029
• Table 21 : Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2029
• Table 22 : Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2029
• Table 23 : FDA Approved DMTs
• Table 24 : Global Neurology Market for Multiple Sclerosis Therapeutics, by Region, Through 2029
• Table 25 : Global Neurology Market for Other Disease Therapeutics, by Region, Through 2029
• Table 26 : Global Neurology Market, by Region, Through 2029
• Table 27 : North American Neurology Market, by Disease Indication, Through 2029
• Table 28 : North American Neurology Market, by Country, Through 2029
• Table 29 : U.S. Neurology Market, by Disease Indication, Through 2029
• Table 30 : Canadian Neurology Market, by Disease Indication, Through 2029
• Table 31 : Mexican Neurology Market, by Disease Indication, Through 2029
• Table 32 : European Neurology Market, by Disease Indication, Through 2029
• Table 33 : European Neurology Market, by Country, Through 2029
• Table 34 : German Neurology Market, by Disease Indication, Through 2029
• Table 35 : U.K. Neurology Market, by Disease Indication, Through 2029
• Table 36 : French Neurology Market, by Disease Indication, Through 2029
• Table 37 : Spanish Neurology Market, by Disease Indication, Through 2029
• Table 38 : Italian Neurology Market, by Disease Indication, Through 2029
• Table 39 : Rest of European Neurology Market, by Disease Indication, Through 2029
• Table 40 : Asia-Pacific Neurology Market, by Disease Indication, Through 2029
• Table 41 : Asia-Pacific Neurology Market, by Country, Through 2029
• Table 42 : Chinese Neurology Market, by Disease Indication, Through 2029
• Table 43 : Japanese Neurology Market, by Disease Indication, Through 2029
• Table 44 : Indian Neurology Market, by Disease Indication, Through 2029
• Table 45 : Rest of Asia-Pacific Neurology Market, by Disease Indication, Through 2029
• Table 46 : Rest of the World Neurology Market, by Disease Indication, Through 2029
• Table 47 : Key Companies in Alzheimer's Generic Drug Market
• Table 48 : Key Companies in Alzheimer's Branded Drug Market
• Table 49 : Global Ranking of Leading Manufacturers of ASD Drugs
• Table 50 : Information Sources in this Report
• Table 51 : Abbreviations Used in the Global Neurology Market Report
• Table 52 : AbbVie Inc.: Company Snapshot
• Table 53 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
• Table 54 : AbbVie Inc.: Product Portfolio
• Table 55 : AbbVie Inc: News/Key Developments, 2023 and 2024
• Table 56 : Alpha Cognition: Company Snapshot
• Table 57 : Alpha Cognition: Financial Performance, FY 2022 and 2023
• Table 58 : Alpha Cognition.: Product Portfolio
• Table 59 : Alpha Cognition: News/Key Developments, 2024
• Table 60 : Biogen.: Company Snapshot
• Table 61 : Biogen: Financial Performance, FY 2022 and 2023
• Table 62 : Biogen: Product Portfolio
• Table 63 : Biogen: News/Key Developments, 2023 and 2024
• Table 64 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 65 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
• Table 66 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 67 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024
• Table 68 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 69 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 70 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 71 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
• Table 72 : Eisai Co. Ltd.: Company Snapshot
• Table 73 : Eisai Co. Ltd..: Financial Performance, FY 2022 and 2023
• Table 74 : Eisai Co. Ltd.: Product Portfolio
• Table 75 : Eisai Co. Ltd.: News/Recent Developments, 2023 and 2024
• Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
• Table 80 : H. Lundbeck A/S: Company Snapshot
• Table 81 : H. Lundbeck A/S: Financial Performance, FY 2022 and 2023
• Table 82 : H. Lundbeck A/S: Product Portfolio
• Table 83 : H. Lundbeck A/S: News/Key Developments, 2021 and 2024
• Table 84 : Lilly: Company Snapshot
• Table 85 : Lilly: Financial Performance, FY 2022 and 2023
• Table 86 : Lilly: Product Portfolio
• Table 87 : Lilly: News/Key Developments, 2024
• Table 88 : Merck & Co. Inc.: Company Snapshot
• Table 89 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
• Table 90 : Merck & Co. Inc.: Product Portfolio
• Table 91 : Merck & Co. Inc.: News/Key Developments, 2023
• Table 92 : Novartis AG: Company Snapshot
• Table 93 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 94 : Novartis AG: Product Portfolio
• Table 95 : Novartis AG: News/Key Developments, 2022 and 2023
• Table 96 : Otsuka Holdings Co. Ltd.: Company Snapshot
• Table 97 : Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 98 : Otsuka Holdings Co. Ltd.: Product Portfolio
• Table 99 : Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024
• Table 100 : Sanofi: Company Snapshot
• Table 101 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 102 : Sanofi: Product Portfolio
• Table 103 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 104 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
• Table 105 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 106 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023
• Table 107 : UCB S.A.: Company Snapshot
• Table 108 : UCB S.A.: Financial Performance, FY 2022 and 2023
• Table 109 : UCB S.A.: Product Portfolio
• Table 110 : UCB S.A.: News/Key Developments, 2024

List of Figures

• Summary Figure : Global Neurology Market Share, by Disease Indication, 2023
• Figure 1 : Porter's Five Forces Analysis of the Neurology Market
• Figure 2 : Market Dynamics of Neurology Market
• Figure 3 : Breakdown of People Aging 65 or Older with Alzheimer's Dementia, 2024
• Figure 4 : Global Burden of Conditions Affecting the Nervous System, 2021
• Figure 5 : Pipeline Analysis of Some Neurological drugs, by Phases, 2024
• Figure 6 : Global Neurology Market Share, by Disease Indication, 2023
• Figure 7 : Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2023
• Figure 8 : Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2023
• Figure 9 : Global Neurology Market Share for Alzheimer Drugs, by Mechanism of Action, 2023
• Figure 10 : Global Neurology Market Share for Alzheimer Drugs, by Region, 2023
• Figure 11 : Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2023
• Figure 12 : Global Neurology Market Share for Antipsychotic Drugs, by Region, 2023
• Figure 13 : Prevalence of Mental Illnesses in U.S. Adult Populations, 2023
• Figure 14 : Global Neurology Market Share for Anti-Epileptic Drugs, by Drug Class, 2023
• Figure 15 : Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2023
• Figure 16 : Global Neurology Market Share for ASD Therapeutics, by Label Information, 2023
• Figure 17 : Global Neurology Market Share for ASD Therapeutics, by Region, 2023
• Figure 18 : Global Market Share of Brain and Central Nervous System Cases, both Sexes, by WHO Region, 2022
• Figure 19 : Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2023
• Figure 20 : Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2023
• Figure 21 : Prevalence of Multiple Sclerosis Cases in Select Countries, 2019
• Figure 22 : Global Neurology Market Share for Multiple Sclerosis Therapeutics, by Region, 2023
• Figure 23 : Global Neurology Market Share for Other Disease Therapeutics, by Region, 2023
• Figure 24 : Global Neurology Market Share, by Region, 2023
• Figure 25 : North American Neurology Market, by Disease Indication, 2021-2029
• Figure 26 : North American Neurology Market Share, by Country, 2023
• Figure 27 : European Neurology Market, by Disease Indication, 2021-2029
• Figure 28 : European Neurology Market Share, by Country, 2023
• Figure 29 : Asia-Pacific Neurology Market, by Disease Indication, 2021-2029
• Figure 30 : Asia-Pacific Neurology Market Share, by Country, 2023
• Figure 31 : Rest of the World Neurology Market, by Disease Indication, 2021-2029
• Figure 32 : Share of Major Players in Anti-Parkinson's Drugs Market, 2023
• Figure 33 : Share of Major Players in Antipsychotic Drugs Market, 2023
• Figure 34 : Share of Major Players in Anti-Epileptic Drugs Market, 2023
• Figure 35 : Share of Major Players in Brain Tumor Therapeutics Market, 2023
• Figure 36 : Share of Major Players in Multiple Sclerosis Therapeutics Market, 2023
• Figure 37 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 38 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 39 : Biogen: Revenue Share, by Business Unit, FY 2023
• Figure 40 : Biogen: Revenue Share, by Country/Region, FY 2023
• Figure 41 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
• Figure 42 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
• Figure 43 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
• Figure 44 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
• Figure 45 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 46 : Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023
• Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 49 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023
• Figure 50 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023
• Figure 51 : Lilly: Revenue Share, by Business Unit, FY 2023
• Figure 52 : Lilly: Revenue Share, by Country/Region, FY 2023
• Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 54 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 55 : Novartis AG: Revenue Share, by Business Unit, FY 2023
• Figure 56 : Novartis AG: Revenue Share, by Country/Region, FY 2023
• Figure 57 : Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 58 : Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 59 : Sanofi: Revenue Share, by Business Unit, FY 2023
• Figure 60 : Sanofi: Revenue Share, by Country/Region, FY 2023
• Figure 61 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 62 : UCB S.A.: Revenue Share, by Business Unit, FY 2023
• Figure 63 : UCB S.A.: Revenue Share, by Country/Region, FY 2023

The global market for neurology is estimated to increase from $67.3 billion in 2024 to reach $94.8 billion by 2029, at a compound annual growth rate (CAGR) of 7.1% from 2024 through 2029.

The multiple sclerosis market for neurology is estimated to increase from $22.5 billion in 2024 to reach $27.2 billion by 2029, at a CAGR of 3.9% from 2024 through 2029.

The brain tumor market for neurology is estimated to increase from $2.9 billion in 2024 to reach $5.3 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.

Report Scope

This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market's drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.

The report breaks down neurology market shares according to various disease indications. Parkinson's disease, Alzheimer's disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.

Anti-Parkinson's medications are covered in the Parkinson's disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson's drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer's disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.

Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

• 52 data tables and 59 additional tables
• Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region
• Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage
• Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals
• A patent analysis, including key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Porter's Five Forces Analysis
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute Products or Services (Moderate to High)
• Industry Rivalry (High)
• Medical Coding and Billing Challenges in Neurology
• Step Therapy
• Medicare Cuts
• Coding errors
• Use of Modifiers
• Documentation
• Coverage and Prior Authorization
• Compliance and Audits
• Reimbursement Rate and Denials
• Physician Payment Challenges
• Evaluation and Management (E/M) - Bill the Correct Level of Care
• Negotiating Contracts

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Growing Geriatric Population with Neurological Disorders
• Increasing Global Incidence of Neurological Disorders
• Government and NGO Initiatives in Creating Awareness
• Research Initiatives in Neurology
• Market Restraints
• Patent Expirations of Branded Drugs and Emergence of Generics
• Adverse Side Effects
• High Cost of Drug Development

Chapter 4 Emerging Trends and Pipeline Analysis

• Emerging Trends
• Precision Medicine in Neurological Disorders
• Gene Therapy for Neurological Disorders
• Neurodegeneration and Stem Cell Therapy
• Nanotechnology in Neuroscience
• Virtual Reality and Digital Therapeutics
• Conclusion
• Pipeline Analysis

Chapter 5 Regulatory Landscape

• Overview
• Cross-Disciplinary Value Story
• High-Quality Patient-Reported Outcome Data
• Impact of New EU and the U.S. Legislation
• Conclusion

Chapter 6 Market Segmentation Analysis

• Segmental Breakdown
• Market Analysis by Disease Indication
• Parkinson's Disease
• Alzheimer's Disease
• Psychotic Disorders
• Epileptic Disorder
• Autism Spectrum Disorder
• Brain Tumor
• Multiple Sclerosis
• Others
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Company Share Analysis of Anti-Parkinson's Drugs
• Company Share Analysis of Alzheimer's Disease Drugs
• Company Share Analysis of Antipsychotic Drugs
• Company Share Analysis of Anti-Epileptic Drugs
• Company Share Analysis of ASD Therapeutics
• Company Share Analysis of Brain Tumor Therapeutics
• Company Share Analysis of Multiple Sclerosis Therapeutics

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ALPHA COGNITION
• BIOGEN
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• OTSUKA HOLDINGS CO. LTD.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• UCB S.A.